Podcasts about GI

Host: Darryl S. Chutka, M.D. Guest: Edward V. Loftus JR, M.D. Inflammatory Bowel Disease is somewhat of an umbrella term for a group of chronic inflammatory conditions of the GI tract. The most common types include ulcerative colitis and Crohn's Disease. While there are similarities between the two, there are also differences. For many individuals with inflammatory bowel disease, it's only a mild illness. Unfortunately for some, it can lead to severe disability and potentially life-threatening complications. What are the similarities and differences between ulcerative colitis and Crohn's? When should we suspect a patient has an inflammatory bowel disease? What's the best way to establish a diagnosis and finally, what treatment options do we have? These are just some of the questions I'll be asking my guest, Edward V. Loftus JR, M.D., from the Division of Gastroenterology and Hepatology at the Mayo Clinic as we discuss “Inflammatory Bowel Disease and Its Treatment”. https://ce.mayo.edu/content/mayo-clinic-talks-inflammatory-bowel-disease Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts 

Tựa Đề: Điều Kiện Để Theo Chúa Giê-xu; Kinh Thánh: Lu-ca 9:57-62; Tác Giả: Mục Sư Vũ Tuấn Anh; Loạt Bài: Hội Thánh Tin Lành Mỹ Đình

Netflix's Korean drama Squid Game became a worldwide phenomenon, winning six Emmys and inspiring countless Halloween costumes. The series has now reached its bloody finale. As the current game concludes, more people die and we find out whether Gi-hun (Lee Jung-jae) and others can finally end the games for good.To access bonus episodes and sponsor-free listening for Pop Culture Happy Hour, subscribe to Pop Culture Happy Hour+ at plus.npr.org/happy.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Nghe trọn nội dung sách nói 7 Thói Quen Hiệu Quả trên ứng dụng Voiz FM: https://voiz.vn/play/1383/Tác phẩm 7 Thói Quen Hiệu Quả (7 Habits For Highly Effective People) đã ra đời hơn 30 năm, được biết đến là cuốn sách quản trị (quản trị bản thân và quản trị tổ chức) bán chạy nhất mọi thời đại với hơn 30 triệu bản bán ra trên toàn thế giới và được dịch sang 40 ngôn ngữ. Sách có mặt tại thị trường Việt Nam hơn 10 năm nay dưới cái tên 7 Thói Quen Để Thành Đạt. Ấn bản mới năm 2016 được đặt lại đúng với cái tên mộc mạc vốn có của bản gốc Tiếng Anh và có nội dung không chỉ được dịch lại toàn bộ cho sát nghĩa, dễ đọc hơn với các độc giả mà còn được cập nhật thêm những công cụ và ví dụ thực tiễn từ phiên bản nước ngoài mới nhất và có hình ảnh bìa (màu xanh đậm) giống với phiên bản gốc mới nhất.Trích lời giới thiệu của nhà giáo Giản Tư Trung - tác giả sách Đúng Việc (lời giới thiệu chỉ có trong ấn bản tiếng Việt được dịch bởi FranklinCovey Việt Nam). Tên đầy đủ của cuốn sách này, nếu dịch sát nghĩa sẽ là: 7 Thói Quen Của Người Có Hiệu Quả Vượt Trội còn nếu dịch một cách ngắn gọn nhưng vẫn sâu sắc sẽ là 7 Thói Quen Hiệu Quả. Gần như Stephen Covey đã dành cả cuộc đời mình để nghiên cứu về tính hiệu quả của con người, để đi tìm câu trả lời cho ba câu hỏi lớn lao, đó là: Vì sao con người ta trở nên ít hiệu quả? Điều gì làm cho con người ta trở nên hiệu quả cao? Điều gì tạo nên hiệu quả bền vững? 7 Habits chính là sự đúc kết sự nghiệp nghiên cứu cả đời của ông cho ba câu hỏi mang tính "muôn đời" đó.Tại ứng dụng sách nói Voiz FM, sách nói 7 Thói Quen Hiệu Quả được đầu tư chất lượng âm thanh và thu âm chuyên nghiệp, tốt nhất để mang lại trải nghiệm nghe tuyệt vời cho bạn.---Về Voiz FM: Voiz FM là ứng dụng sách nói podcast ra mắt thị trường công nghệ từ năm 2019. Với gần 2000 tựa sách độc quyền, Voiz FM hiện đang là nền tảng sách nói podcast bản quyền hàng đầu Việt Nam. Bạn có thể trải nghiệm miễn phí đa dạng nội dung tại Voiz FM từ sách nói, podcast đến truyện nói, sách tóm tắt và nội dung dành cho thiếu nhi.---Voiz FM website: https://voiz.vn/ Theo dõi Facebook Voiz FM: https://www.facebook.com/VoizFM Tham khảo thêm các bài viết review, tổng hợp, gợi ý sách để lựa chọn sách nói dễ dàng hơn tại trang Blog Voiz FM: http://blog.voiz.vn/---Cảm ơn bạn đã ủng hộ Voiz FM. Nếu bạn yêu thích sách nói 7 Thói Quen Hiệu Quả và các nội dung sách nói podcast khác, hãy đăng ký kênh để nhận thông báo về những nội dung mới nhất của Voiz FM channel nhé. Ngoài ra, bạn có thể nghe BẢN FULL ĐỘC QUYỀN hàng chục ngàn nội dung chất lượng cao khác tại ứng dụng Voiz FM.Tải ứng dụng Voiz FM: voiz.vn/download#voizfm #sáchnói #podcast #sáchnói7ThóiQuenHiệuQuả #StephenRCovey

This week Gi is joined by fashion designer and queen of colour Olivia Rubin!Olivia talks about balancing the success of her growing business with parenting her two daughters, and tells Gi why she's decided to scale things back.Olivia also opens up about struggling mentally after the birth of her first child. As postnatal mental health was rarely spoken about, Olivia admits at the time she didn't know what she was experiencing, Hosted on Acast. See acast.com/privacy for more information.

Testing and Treatment Dr's Sand, Kapadia and Gurevich do a deep dive into SIFO, Small Intestinal Fungal Overgrowth. In this episode Dr. Kapadia leads us in a discussion of fungal overgrowth in the GI tract. Topics covered: Symptoms Testing and Treatment of SIFO, Organic Acid Testing, Stool Testing, Protozoa, tongue coating, association with allergies, MCAS, skin, Vulvovaginitis and candidiasis, IBS, IBD and SIFO, Biofilm and SIFOLinks to Dr. Kapadia's courses on SIFO:Practitioner course on SIFO and Mold: ⁠https://drkapadia.teachable.com/p/a-minimalist-s-approach-to-mold-related-illness-and-small-intestinal-fungal-overgrowth-sifo⁠

Host: Darryl S. Chutka, M.D. Guests: David H. Bruining, M.D., and Nayantara Coelho-Prabhu, M.B.B.S. An early diagnosis of inflammatory bowel disease is important in preventing long-term complications. Prompt treatment can improve quality of life, reduce the likelihood of hospitalizations, and help maintain remissions. However, establishing a diagnosis is often challenging due to the nonspecific and fluctuating nature of symptoms. Inflammatory bowel disease can also mimic other GI conditions. In addition, diagnostic confirmation usually requires a combination of blood tests, imaging, endoscopy, and histological analysis, making the process both time consuming and complex.  The topic for today's podcast is “Diagnosing Inflammatory Bowel Disease and Monitoring Modalities” and my guests are David H. Bruining, M.D., and Nayantara Coelho-Prabhu, M.B.B.S., from the Division of Gastroenterology and Hepatology at the Rochester campus of the Mayo Clinic. https://ce.mayo.edu/content/mayo-clinic-talks-inflammatory-bowel-disease   Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts   

Tin tức đáng chú ý: Giảm một nửa mức thu hơn 40 khoản phí, lệ phí; Quy định mới từ 1-7 doanh nghiệp cần lưu ý; TP.HCM cảnh báo khẩn dầu phong thấp Trường Thọ giả...

Là cầu thủ gốc Việt (sinh ra tại Mỹ với mẹ là người Việt) đầu tiên thi đấu tại Giải bóng rổ nhà nghề Mỹ (NBA), Jaylin Williams vừa ký hợp đồng trị giá 24 triệu USD, là một trong những cầu thủ có mức lương cao nhất làng bóng rổ thế giới.

Today, hosts Michael and Josh are joined by the wonderful Dr James McCracken to discuss highlights from ASCO 2025 in the areas of upper GI and hepatobiliary cancer. This episode focuses on two items that are (as Michael repetitively insists) "big ticket": MATTERHORN and Destiny-Gastric04. In addition, James gives his thoughts on studies that look at immunotherapy and novel neoadjuvant chemotherapy in pancreatic cancer, and a small study examining a perioperative approach to resectable biliary tract cancer.Studies discussed in the episode:MATTERHORNDestiny-Gastric04NeoIMPACTCASSANDRAGAINFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Laudetur Jesus Christus - Ngợi khen Chúa Giêsu KitôRadio Vatican hằng ngày của Vatican News Tiếng Việt.Nội dung chương trình hôm nay:0:00 Bản tin15:01 Ciao Bạn trẻ : Những người trẻ đồng hành với trẻ em nghèo - phần 1---Những hình ảnh này thuộc Bộ Truyền Thông của Toà Thánh. Mọi sử dụng những hình ảnh này của bên thứ ba đều bị cấm và dẫn đến việc đánh bản quyền, trừ khi được cho phép bằng giấy tờ của Bộ Truyền Thông. Copyright © Dicasterium pro Communicatione - Giữ mọi bản quyền.

VOV1 - Chiều 29/6, tại Thành phố Hồ Chí Minh, Tổng Bí thư Tô Lâm cùng Đoàn công tác của Trung ương đã đi khảo sát thực tế mô hình tổ chức chính quyền địa phương 2 cấp tại phường Xuân Hòa và xã Tân Vĩnh Lộc (2 trong số 168 đơn vị hành chính mới của Thành phố Hồ Chí Minh).- Tổng Bí thư có bài viết nhan đề "Sức mạnh của đoàn kết", nhấn mạnh việc gìn giữ đoàn kết là nhiệm vụ hàng đầu, điều kiện tiên quyết để mọi công việc cải cách diễn ra thuận lợi. Đài TNVN trân trọng giới thiệu toàn văn bài viết này-Khởi công cao tốc Bảo Lộc – Liên Khương, giúp rút ngắn thời gian chặng TPHCM - Đà Lạt từ 6 giờ còn hơn 3 giờ-Lần đầu tiên trưng bày 17 Bảo vật quốc gia tại TPHCM-Vụ cháy nhà xưởng tại Hưng Yên làm 5 người chết và 2 người bị thương một lần nữa gióng lên hồi chuông cảnh báo về lỗ hổng trong công tác phòng cháy, chữa cháy tại các khu công nghiệp và làng nghề- Thượng viện Mỹ nhất trí thảo luận dự luật chi tiêu gây tranh cãi của Tổng thống Đô-nan Trăm- Iran không cho phép Tổng Giám đốc Cơ quan Năng lượng Nguyên tử Quốc tế thanh sát các cơ sở hạt nhân của nước này

Laudetur Jesus Christus - Ngợi khen Chúa Giêsu KitôRadio Vatican hằng ngày của Vatican News Tiếng Việt.Nội dung chương trình hôm nay:0:00 Thánh Lễ trọng kính hai thánh Phêrô và Phaolô09:17 Kinh Truyền Tin17:31 Giáo hội tuần qua---Những hình ảnh này thuộc Bộ Truyền Thông của Toà Thánh. Mọi sử dụng những hình ảnh này của bên thứ ba đều bị cấm và dẫn đến việc đánh bản quyền, trừ khi được cho phép bằng giấy tờ của Bộ Truyền Thông. Copyright © Dicasterium pro Communicatione - Giữ mọi bản quyền.

Góc nhìn của Giáo sư Phan Văn Trường về việc có cần người cổ vũ tinh thần hay không? Theo Thầy, tinh thần tự tại mới là điều quan trọng nhất. Hãy cùng lắng nghe câu hỏi hôm nay và chia sẻ của Thầy Trường nhé!Đăng ký theo dõi Cấy Nền Radio: https://www.youtube.com/c/CayNenRadio-------------------------------ツ Kết nối với Cấy Nền Radio:► Tik Tok: https://www.tiktok.com/@caynenradio► Fanpage Facebook: https://www.facebook.com/caynenradio► Youtube duy nhất: https://www.youtube.com/@CayNenRadio► Spotify: https://bit.ly/CayNenRadio_Spotify ► Linkedin: https://www.linkedin.com/company/caynenradio► Group Facebook: https://www.facebook.com/groups/CayNenRadio/Bản quyền Video thuộc về CẤY NỀN RADIO | Không re-up dưới mọi hình thức.Mọi vấn đề về bản quyền xin liên hệ:

Tựa Đề: Chúa Giê-xu, Đấng Nhu Mì; Kinh Thánh: Ma-thi-ơ 21:1-6; Tác Giả: VPNS; Loạt Bài: Sống Với Thánh Kinh, Bài Học Kinh Thánh Hằng Ngày, Tĩnh Nguyện Hằng Ngày, Sống Với Thánh Kinh

A DIVISIVE ENDING!! Squid Game Season 3 Full Reaction Watch Along:   / thereelrejects   Visit https://huel.com/rejects to get 15% off your order Gi-Hun Dies, Cate Blanchett cameo, Holy Moly! Squid Game Season 3 Reaction, Recap, Commentary, Analysis, Spoiler Review, Breakdown, & Ending Explained! Greg Alba & John Humphrey dive into the intense Squid Game Season 3 Episode 6 finale—breaking down the emotional final duel, Gi-hun's shocking death, the Front Man's Los Angeles visit, and Cate Blanchett's surprise recruiter cameo that sets up the rumored Squid Game USA spin-off. We analyze the heartbreaking “Sky Squid Game” on collapsing towers, Seong Gi-hun vs. Myung-gi's final fight, and the soul-crushing moment when Gi-hun sacrifices himself to save Jun-hee's baby, Player 222. We cover how the island's countdown self-destruction changes the Squid Game forever and unpack the meaning behind the Front Man delivering Gi-hun's tracksuit to his daughter in L.A. Plus, we discuss the baby winning Squid Game and how Cate Blanchett's recruiter scene mirrors Gong Yoo's iconic train station moment. Join us as we explore what's next: Squid Game USA, the possible David Fincher spin-off, and the bold future of the Squid Game franchise! Drop your theories in the comments: Did Gi-hun really have to die? Will the U.S. version be even more brutal? Subscribe for more Netflix reactions, Korean drama reviews, and Squid Game breakdowns! Intense Suspense by Audionautix is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/... Support The Channel By Getting Some REEL REJECTS Apparel! https://www.rejectnationshop.com/ Follow Us On Socials:  Instagram: https://www.instagram.com/reelrejects/  Tik-Tok: https://www.tiktok.com/@reelrejects?lang=en Twitter: https://x.com/reelrejects Facebook: https://www.facebook.com/TheReelRejects/ Music Used In Ad:  Hat the Jazz by Twin Musicom is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Happy Alley by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/... POWERED BY @GFUEL Visit https://gfuel.ly/3wD5Ygo and use code REJECTNATION for 20% off select tubs!! Head Editor: https://www.instagram.com/praperhq/?hl=en Co-Editor: Greg Alba Co-Editor: John Humphrey Music In Video: Airport Lounge - Disco Ultralounge by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Ask Us A QUESTION On CAMEO: https://www.cameo.com/thereelrejects Follow TheReelRejects On FACEBOOK, TWITTER, & INSTAGRAM:  FB:  https://www.facebook.com/TheReelRejects/ INSTAGRAM:  https://www.instagram.com/reelrejects/ TWITTER:  https://twitter.com/thereelrejects Follow GREG ON INSTAGRAM & TWITTER: INSTAGRAM:  https://www.instagram.com/thegregalba/ TWITTER:  https://twitter.com/thegregalba Learn more about your ad choices. Visit megaphone.fm/adchoices

VOV1 - Năm 2025, du lịch Việt Nam tiếp tục ghi dấu ấn trên bản đồ thế giới khi TP.HCM và Phú Quốc được vinh danh tại Giải thưởng châu Á – Thái Bình Dương.- Lãnh đạo Đảng, Nhà nước Việt Nam chúc mừng 74 năm ngày thành lập Đảng Nhân dân Campuchia.- Thủ tướng Phạm Minh Chính chủ trì cuộc họp xem xét, giải quyết các quan tâm của phía Hoa Kỳ liên quan thương mại, thuế quan; làm việc với  các doanh nghiệp Vương quốc Anh đang hoạt động đầu tư, sản xuất, kinh doanh tại Việt Nam.- Cục Hàng không Việt Nam điều tra xác minh nguyên nhân sự cố vụ hai máy bay va chạm nhau tại Sân bay Nội Bài.- Bắc Bộ mưa lớn, cục bộ có nơi 500 mm. Các địa phương chủ động lên phương án phòng tránh.- Tòa án Tối cao Mỹ ra phán quyết cho phép chính quyền Tổng thống Donald Trump thực hiện kế hoạch loại bỏ quyền lấy quốc tịch theo nơi sinh.- Các nhà khoa học tại Australia  đạt được đột phá trong nghiên cứu y học khi tạo thành công mô tim thu nhỏ nuôi cấy trong phòng thí nghiệm, mở ra triển vọng mới trong việc điều trị các bệnh tim di truyền hiếm gặp ở trẻ em.

Tựa Đề: Chúa Giê-xu, Đấng Nhu Mì; Kinh Thánh: Ma-thi-ơ 21:1-6; Tác Giả: VPNS; Loạt Bài: Sống Với Thánh Kinh, Bài Học Kinh Thánh Hằng Ngày, Tĩnh Nguyện Hằng Ngày, Sống Với Thánh Kinh

Edo Bricchetti"Andar per abbazie"Meravigli Edizioniwww.meravigliedizioni.itOggi si parla, a ragion veduta, della “Strada delle Abbazie”, un cammino che unisce idealmente la chiesa di San Pietro in Gessate, l'abbazia di Monluè, l'abbazia di Chiaravalle, la basilica di Santa Maria in Calvenzano (Vizzolo Predabissi), l'abbazia di Viboldone (San Giuliano M.), l'abbazia di Mirasole (Opera), l'abbazia di Morimondo e la certosa di Garegnano. Nonostante non sia ormai più in vigore in tutte l'originaria regola monastica, il potere evocativo delle loro architetture e degli straordinari scrigni di storia e arte racchiusi al loro interno riescono a regalarci la scoperta e lo stupore di una visita che appaga l'occhio e fa riposare la mente.Dietro la guida appassionata e appassionante di Edo Bricchetti, un prezioso volume dal ricco apparato iconografico, che ci conduce in un sorprendente viaggio a chilometro zero.Edo Bricchetti (Milano, 1946), umanista e architetto, ha insegnato al Politecnico e all'Università Bicocca. È membro del Board dell'I.W.I. (Inland Waterways International), consigliere regionale ICOM (International Council of Museums), referente dei Paesaggi Culturali della Rete degli Ecomusei Lombardi, membro del Comitato Tecnico della Consulta degli Ecomusei Lombardi. Animatore di progetti europei sui beni culturali materiali, immateriali e paesaggistici, è ideatore e progettista di: Ecomuseo Adda di Leonardo, Ecomuseo Martesana, Ecomuseo Valvarrone, Ecomuseo Valle Spluga, Ecomuseo del Distretto dei monti e laghi briantei. Già membro del Comitato Tecnico Scientifico dei “Percorsi di Leonardo” (Navigli Lombardi s.c.a.r.l.) per la promozione e la valorizzazione culturale e turistica del Sistema Navigli. Il Ministero per i Beni Culturali e Ambientali, Commissione Nazionale per i Beni Culturali industriali, gli ha conferito un attestato di benemerenza per la sua opera pluridecennale nel campo dell'archeologia industriale. A seguito dei suoi studi sulle vie d'acqua interne è stato nominato “Custode delle Acque”. Dalla Fondazione dei Rotary International ha ricevuto il titolo di “Paul Harris Fellow” in segno di apprezzamento e riconoscenza per il suo tangibile e significativo apporto nel promuovere una migliore comprensione reciproca e amichevoli relazioni fra i popoli di tutto il mondo. Al suo attivo ha numerosi libri. Per Meravigli ha pubblicato Il Naviglio Grande è bello anche in bici e Naviglio Pavese e di Bereguardo belli anche in bici (nella collana “Andar per Navigli”, di cui è curatore); Navigli del Milanese ieri e oggi (con testi di Giuseppe Codara); I Navigli di Milano – Viaggio pittorico; Borghi milanesi del Naviglio Piccolo (in collaborazione con sua figlia Alessandra); Leonardo: la pittura, i navigli, l'acqua; Storia e storie degli antichi borghi milanesi; Corpi Santi – Storia e storie del Comune che circondava Milano; Andar per abbazie.IL POSTO DELLE PAROLEascoltare fa pensarewww.ilpostodelleparole.itDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.

Laudetur Jesus Christus - Ngợi khen Chúa Giêsu KitôRadio Vatican hằng ngày của Vatican News Tiếng Việt.Nội dung chương trình hôm nay:00:00 Bản Tin17:37 Bước từng bước | Truyện ngắn: Ký ức của một thai nhi

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Tựa Đề: Giữ Lấy Mình; Tác Giả: M. Jeudi; Loạt Bài: Hạt Giống Tốt

Giá nhà sẽ còn tiếp tục tăng, giấc mơ sở hữu nhà dần xa tầm với của giới trẻ và khoảng cách giàu nghèo vẫn tiếp tục nới rộng.

BGVV-1590_Thầy Giảng Ngày Khánh Thành TÐ Gudruvet Ðan Mạch_Montreal_28-08-1985Vô Vi Podcast-Vấn ĐạoVô Vi Podcast-Bài GiảngVô Vi Podcast-Nhạc Thiền

Etterforskningen mot Marius Borg Høiby er ferdig. I siktelsen finner vi et tosifret antall fornærmede. Erna Solberg lover tusen nye politifolk, og styrtrike Jeff Bezos setter vakre Venezia på hodet. Med Sindre Heyerdahl, Frøy Gudbrandsen, Selma Moren og Torbjørn Røe Isaksen. Produsent Fredrik Johansen. Ansvarlig redaktør Gard Steiro. Kontakt redaksjonen på giaeveroggjengen@vg.no. Giæver & gjengen gir deg de viktigste nyhetene hver dag på drøye 20 minutter når du skal hjem fra jobb. Hør «Mediebobler» hver lørdag om feilene pressen gjør og dilemmaer VG står i. Hør «Skartveit» med interessante personer om aktuelle temaer hver søndag. Alltid på Podme.

#Bàigiảng của Lm Phanxicô Xaviê Bảo Lộc trong thánh lễ kính Thánh Tâm Chúa Giêsu, cử hành lúc 17:30 ngày 27-6-2025 tại Nhà nguyện Trung tâm Mục vụ #TGPSG

A GAME OF KILLER HIDE AND SEEK!! Squid Game Season 3 Full Reaction Watch Along:   / thereelrejects   Visit https://huel.com/rejects to get 15% off your order The FINAL Season is here & it's time for our Squid Game Season 3 Reaction, Recap, Breakdown, Commentary, Spoiler Review & ending explained!! Greg Alba & John Humphrey return to the dystopian playground in Netflix's final and explosive Squid Game season, with Episodes 1 & 2 premiering June 27, 2025. After the violent uprising of Season 2, Season 3 opens with Seong Gi‑hun (Lee Jung‑jae, Train to Busan), dubbed Player 456, wheeled back in via a coffin in a chilling first scene. Haunted by survivor's guilt, he's emotionally shattered and driven by the crushing need for justice and revenge. The two episodes thrust us into a deranged version of “Hide-and-Seek,” with red and blue teams battling for life, intensified by cold psychological stakes. Gi‑hun's fractured alliance with Dae-ho (Kang Ha‑neul, Forgotten, Midnight Runners) and the return of detective Jun-ho (Wi Ha‑joon, Money Heist, Something in the Rain) deepens the narrative. Jun-ho's quest continues as he searches for his brother, the enigmatic Front Man (Lee Byung‑hun, G.I. Joe, Masters of the Universe)—infiltrating both the games and the inner workings of the Institute. Standout moments include: Gi‑hun's silent breakdown and explosive confrontation with Dae‑ho, The grotesquely thrilling Hide-and-Seek game, Jun‑ho's investigative breakthrough and near-encounter with betrayals inside the Island's power structure, & more! Main cast stars include Lee Jung‑jae as Gi‑hun, Lee Byung‑hun as the Front Man, Wi Ha‑joon as Jun‑ho, Kang Ha‑neul's cunning Dae‑ho, Park Gyu‑young as No‑eul, Im Si‑wan, Park Sung‑hoon, Jo Yu‑ri, and more, bringing fresh tension and emotional arcs to the final season. This gritty, emotionally haunted premiere sets the tone for a savage descent into the games' conclusion. Join Greg & John as they unpack every twist, alliance, and horrifying moment in Squid Game's last season! Intense Suspense by Audionautix is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/... Support The Channel By Getting Some REEL REJECTS Apparel! https://www.rejectnationshop.com/ Follow Us On Socials:  Instagram: https://www.instagram.com/reelrejects/  Tik-Tok: https://www.tiktok.com/@reelrejects?lang=en Twitter: https://x.com/reelrejects Facebook: https://www.facebook.com/TheReelRejects/ Music Used In Ad:  Hat the Jazz by Twin Musicom is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Happy Alley by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/... POWERED BY @GFUEL Visit https://gfuel.ly/3wD5Ygo and use code REJECTNATION for 20% off select tubs!! Head Editor: https://www.instagram.com/praperhq/?hl=en Co-Editor: Greg Alba Co-Editor: John Humphrey Music In Video: Airport Lounge - Disco Ultralounge by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Ask Us A QUESTION On CAMEO: https://www.cameo.com/thereelrejects Follow TheReelRejects On FACEBOOK, TWITTER, & INSTAGRAM:  FB:  https://www.facebook.com/TheReelRejects/ INSTAGRAM:  https://www.instagram.com/reelrejects/ TWITTER:  https://twitter.com/thereelrejects Follow GREG ON INSTAGRAM & TWITTER: INSTAGRAM:  https://www.instagram.com/thegregalba/ TWITTER:  https://twitter.com/thegregalba Learn more about your ad choices. Visit megaphone.fm/adchoices

THE DEADLY JUMP ROPE GAME!!! Use REELREJECTS to get 55% off your first month at Scentbird https://sbird.co/43HYPuV This month I received... Charlie by Matthew Zink https://sbird.co/4dT1yGP The Element by NEH https://sbird.co/3FLSpTy Dylan Blue Pour Homme by Versace https://sbird.co/4mPpSNI Burberry for Men EDT by Burberry https://sbird.co/4mOQb6x Squid Game Season 3 Full Reaction Watch Along:   / thereelrejects   With the FINAL SEASON upon us, Greg & John give their Squid Game Season 3 Recap, Commentary, Analysis & Spoiler Review!! Greg Alba & John Humphrey return to the edge of survival in Netflix's explosive final Squid Game season with Episodes 3 (“It's Not Your Fault”) and 4 (“222”). As the competition narrows, Seong Gi‑hun (Lee Jung‑jae, Star Wars: The Acolyte) and his fractured alliance must face one of the season's most infamous challenges yet: a fiendishly deadly jump-rope game once again played at great heights in front of an audience of our favorite over-the-top VIP's... In Episode 4, titled “222,” Gi‑hun finally confronts the masked Front Man (Lee Byung‑hun, G.I. Joe, Masters of the Universe), leading to a dramatic unmasking that shifts the power balance in brutal fashion. The stakes are raised as he's offered a knife and forced to betray his remaining allies—blurring the lines between hero and survivor. Meanwhile, returning players like detective Jun‑ho (Wi Ha‑joon, Money Heist, Something in the Rain) deepen the rescue plot as he climbs closer to the island, while Dae‑ho (Kang Ha‑neul, Forgotten) proves himself in the games again. New blood like Im Si‑wan, Park Gyu‑young, and Jo Yu‑ri bring fresh energy and emotional complexity. Standout moments include the terror of synchronized ropes, the jaw-dropping Front Man reveal, and the moral crumble as players choose survival over solidarity. Critics say Season 3 returns to the series' brutal essence, focusing on psychologically harrowing childlike games with dehumanizing stakes at their core... Tune in with Greg & John as they unpack every tension-fueled game, shocking twist, and heartbreaking choice in these key episodes of the final season! Intense Suspense by Audionautix is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/... Support The Channel By Getting Some REEL REJECTS Apparel! https://www.rejectnationshop.com/ Follow Us On Socials:  Instagram: https://www.instagram.com/reelrejects/  Tik-Tok: https://www.tiktok.com/@reelrejects?lang=en Twitter: https://x.com/reelrejects Facebook: https://www.facebook.com/TheReelRejects/ Music Used In Ad:  Hat the Jazz by Twin Musicom is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Happy Alley by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/... POWERED BY @GFUEL Visit https://gfuel.ly/3wD5Ygo and use code REJECTNATION for 20% off select tubs!! Head Editor: https://www.instagram.com/praperhq/?hl=en Co-Editor: Greg Alba Co-Editor: John Humphrey Music In Video: Airport Lounge - Disco Ultralounge by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/ Ask Us A QUESTION On CAMEO: https://www.cameo.com/thereelrejects Follow TheReelRejects On FACEBOOK, TWITTER, & INSTAGRAM:  FB:  https://www.facebook.com/TheReelRejects/ INSTAGRAM:  https://www.instagram.com/reelrejects/ TWITTER:  https://twitter.com/thereelrejects Follow GREG ON INSTAGRAM & TWITTER: INSTAGRAM:  https://www.instagram.com/thegregalba/ TWITTER:  https://twitter.com/thegregalba Learn more about your ad choices. Visit megaphone.fm/adchoices

Bài Giảng: Tin Lành Có Phải Là Sự Ưu Tiên Của BạnDiễn giả: Mục sư Stuart OllyotChuyển ngữ: Đội ngũ Ba-rúcMục sư Stuart Ollyot, tác giả của cuốn sách "Preaching Pure and Simple" - (tạm dịch "Giảng dạy chân thật và giản dị"), nổi tiếng với những bài giảng sâu sắc nhưng vô cùng chân thành và giản dị của mình. -----------------------------The Giang Luan Kinh Thanh (Biblical Preaching) YouTube channel is dedicated to providing biblically faithful sermons and messages from respected Christian speakers. Our content is specifically designed to uplift and support pastors and believers in Vietnam, where access to resources for Christian teaching can be limited. As a non-profit initiative, our mission is to offer encouragement and spiritual guidance to believers striving to serve God in their communities.We would like to inform you that some videos may not have obtained formal copyright permissions prior to translation. We sincerely appreciate the understanding and forgiveness of copyright holders regarding this matter. If you have any concerns or inquiries, please feel free to reach out to us at giangluankinhthanh@gmail.co-----------------------------Anh chị em có thể nghe bài giảng audio của Giảng Luận Kinh Thánh tại địa chỉ sau:Spotify: https://sum.vn/HybEqApple podcast: https://sum.vn/SccJBGiảng Luận Kinh Thánh là dự án dịch thuật/lồng tiếng sang tiếng Việt các bài giảng, thông điệp Cơ Đốc kinh điển của những diễn giả đã được thời gian khẳng định và cộng đồng Cơ đốc chung xác nhận. Đây là dự án phi lợi nhuận nhằm cung cấp nguồn tư liệu cho các tôi tớ cùng con dân Chúa tham khảo và sử dụng miễn phí. Để hiểu hơn về chúng tôi vui lòng truy cập website :https://giangluankinhthanh.net/Đội ngũ Giảng Luận Kinh Thánh hoan nghênh mọi đề nghị cộng tác của quý con cái Chúa khắp nơi trong các lĩnh vực như dịch thuật, lồng tiếng, quảng bá, cầu thay, v.v. Nếu quý con cái Chúa sẵn lòng đóng góp công sức của mình vào bất cứ lĩnh vực nào, cùng đồng công trong những sứ điệp giúp tỉnh thức nhiều người.Xin vui lòng điền thông tin cá nhân vào biểu mẫu sau: Kênh Giảng Luận Kinh Thánh hoạt động vì các mục tiêu phi lợi nhuận, không phát quảng cáo. Vì vậy, chúng tôi mong tiếp tục nhận được sự dâng hiến và ủng hộ của quý con cái Chúa khắp nơi trong việc phát triển kênh. Quý vị có thể dâng hiến theo thông tin trong biểu mẫu sau: https://sum.vn/ZZ19mNếu bạn muốn dâng hiến cho các hoạt động của Kênh, xin vui lòng chuyển khoản cho chúng tôi vào số tài khoản dưới đây:Tên tài khoản: Nguyen Thanh Tung - Nguyen Dinh HungSố tài khoản VND: 0010174709250 Số tài khoản USD: 0200143705194 Tên ngân hàng: Ngân hàng MB Bank – Chi nhánh Hoài Đức (Military Commercial Joint Stock Bank - Hoai Duc Branch)SWIFT CODE: MSCBVNVXXin chân thành cảm ơn!#Giangluankinhthanh #tinlanh #StuartOllyot #baigiangkinhthanh #baigiangtinlanh #sudiepcodoc

Bài Giảng: Tin Lành Có Phải Là Sự Ưu Tiên Của BạnDiễn giả: Mục sư Stuart OllyotChuyển ngữ: Đội ngũ Ba-rúcMục sư Stuart Ollyot, tác giả của cuốn sách "Preaching Pure and Simple" - (tạm dịch "Giảng dạy chân thật và giản dị"), nổi tiếng với những bài giảng sâu sắc nhưng vô cùng chân thành và giản dị của mình. -----------------------------The Giang Luan Kinh Thanh (Biblical Preaching) YouTube channel is dedicated to providing biblically faithful sermons and messages from respected Christian speakers. Our content is specifically designed to uplift and support pastors and believers in Vietnam, where access to resources for Christian teaching can be limited. As a non-profit initiative, our mission is to offer encouragement and spiritual guidance to believers striving to serve God in their communities.We would like to inform you that some videos may not have obtained formal copyright permissions prior to translation. We sincerely appreciate the understanding and forgiveness of copyright holders regarding this matter. If you have any concerns or inquiries, please feel free to reach out to us at giangluankinhthanh@gmail.co-----------------------------Anh chị em có thể nghe bài giảng audio của Giảng Luận Kinh Thánh tại địa chỉ sau:Spotify: https://sum.vn/HybEqApple podcast: https://sum.vn/SccJBGiảng Luận Kinh Thánh là dự án dịch thuật/lồng tiếng sang tiếng Việt các bài giảng, thông điệp Cơ Đốc kinh điển của những diễn giả đã được thời gian khẳng định và cộng đồng Cơ đốc chung xác nhận. Đây là dự án phi lợi nhuận nhằm cung cấp nguồn tư liệu cho các tôi tớ cùng con dân Chúa tham khảo và sử dụng miễn phí. Để hiểu hơn về chúng tôi vui lòng truy cập website :https://giangluankinhthanh.net/Đội ngũ Giảng Luận Kinh Thánh hoan nghênh mọi đề nghị cộng tác của quý con cái Chúa khắp nơi trong các lĩnh vực như dịch thuật, lồng tiếng, quảng bá, cầu thay, v.v. Nếu quý con cái Chúa sẵn lòng đóng góp công sức của mình vào bất cứ lĩnh vực nào, cùng đồng công trong những sứ điệp giúp tỉnh thức nhiều người.Xin vui lòng điền thông tin cá nhân vào biểu mẫu sau: Kênh Giảng Luận Kinh Thánh hoạt động vì các mục tiêu phi lợi nhuận, không phát quảng cáo. Vì vậy, chúng tôi mong tiếp tục nhận được sự dâng hiến và ủng hộ của quý con cái Chúa khắp nơi trong việc phát triển kênh. Quý vị có thể dâng hiến theo thông tin trong biểu mẫu sau: https://sum.vn/ZZ19mNếu bạn muốn dâng hiến cho các hoạt động của Kênh, xin vui lòng chuyển khoản cho chúng tôi vào số tài khoản dưới đây:Tên tài khoản: Nguyen Thanh Tung - Nguyen Dinh HungSố tài khoản VND: 0010174709250 Số tài khoản USD: 0200143705194 Tên ngân hàng: Ngân hàng MB Bank – Chi nhánh Hoài Đức (Military Commercial Joint Stock Bank - Hoai Duc Branch)SWIFT CODE: MSCBVNVXXin chân thành cảm ơn!#Giangluankinhthanh #tinlanh #StuartOllyot #baigiangkinhthanh #baigiangtinlanh #sudiepcodoc

Laudetur Jesus Christus - Ngợi khen Chúa Giêsu KitôRadio Vatican hằng ngày của Vatican News Tiếng Việt.Nội dung chương trình hôm nay:0:00 Bản tin14:34 Chia sẻ Lời Chúa : Lm. Toma Aquino Nguyễn Khánh Duy, SJ, chia sẻ Lời Chúa Lễ hai thánh Phêrô và Phaolô Tông đồ23:18 Nữ tu trong Giáo hội : Giữa đau khổ do chiến tranh, các nữ tu Ucraina mang an bình và niềm vui cho người dân---Những hình ảnh này thuộc Bộ Truyền Thông của Toà Thánh. Mọi sử dụng những hình ảnh này của bên thứ ba đều bị cấm và dẫn đến việc đánh bản quyền, trừ khi được cho phép bằng giấy tờ của Bộ Truyền Thông. Copyright © Dicasterium pro Communicatione - Giữ mọi bản quyền.

Giải mã công thức “hóa rồng” của đặc khu kinh tế Thâm Quyến | Baram01 | Thế Giới

Laudetur Jesus Christus - Ngợi khen Chúa Giêsu KitôRadio Vatican hằng ngày của Vatican News Tiếng Việt.Nội dung chương trình hôm nay:0:00 Bản tin18:20 Sinh hoạt Giáo hội : Vatican ủng hộ phúc trình kêu gọi cải cách tài chính nhằm giảm bớt cuộc khủng hoảng nợ toàn cầu.---Những hình ảnh này thuộc Bộ Truyền Thông của Toà Thánh. Mọi sử dụng những hình ảnh này của bên thứ ba đều bị cấm và dẫn đến việc đánh bản quyền, trừ khi được cho phép bằng giấy tờ của Bộ Truyền Thông. Copyright © Dicasterium pro Communicatione - Giữ mọi bản quyền.

Send us a textIn the latest episode of 'Clot Conversations,' host David Airdrie and guest Dr. Vinai Bhagirath, alongside a talented group of researchers, delve into groundbreaking thrombosis research presented at ISTH 2025. Highlights include Amulya Bhagirath's work on a computerized decision support system for anticoagulation, Dr. Alejandro Godoy's international study on LMWH bridging in patients with mechanical heart valves, Tegvir Grewal's work on perioperative anticoagulation of mechanical aortic valve patients for GI endoscopy and Julia Sharobim's work on transcatheter aortic valve replacement. These studies underline the importance of innovative approaches in thrombosis management, emphasizing Canada's role in driving global research. With promising new insights and collaborations across the globe, this episode showcases the exciting future of thrombosis research.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

VOV1 - Sáng 26/6, Đoàn công tác của Cơ quan Quản lý Truyền thông Hungary (MTVA) do ông Dániel Papp, Tổng Giám đốc Cơ quan Quản lý Truyền thông Hungary dẫn đầu đã tới thăm, làm việc và ký thỏa thuận hợp tác với Đài Tiếng nói Việt Nam (VOV)

Send us a textOn this episode Al travels to Des Moines Iowa for Subspectrum BJJ While in Iowa he sits down and  Interviews Professor Eddie Davis from The Crucible BJJ They cover a few subjects including JiuJitsu 

In this podcast episode, Miguel Regueiro, MD, discusses developing the medical home model for patients with IBD, technological advances for patients in GI and more. •    Intro :58 •    The interview/about Regueiro 1:03 •    Tell us about your family and where you grew up. 1:24 •    How did you get interested in medicine? 2:16 •    Who were your early influences?  4:18 •    What is the medical home? 5:57 •    How did you develop the idea to apply the medical home model to IBD? 7:45 •    Did you get any funding from the payers for this model to keep costs under control for this patient population? 10:57 •    Why hasn't this model become standard of care for patients with complex IBD? 14:13 •    What has worked, and what hasn't worked when it comes to adopting an integrative care medical home model? 18:15 •    Are there themes patients share as to why they wouldn't want to be enrolled in a medical home? 21:28 •    What motivated your change to go from UPMC to become the GI Chief of Cleveland Clinic? 23:09 •    What have you learned in this position at Cleveland Clinic? 25:23 •    Are you spending a lot of time on the business side of care as opposed to the patient side? 26:34 •    How would you recommend that people prepare for having a position like this? 27:34 •    Are you seeing a shift in excitement over taking on leadership roles outside of traditional academics? 30:02 •    With our clinical tool chest changing so rapidly, is there a common theme that you use to guide the strategy of the institute on what to invest in? 35:06 •    What are the challenges that you still see in the ways we are using telehealth? 39:05 •    What are some of the most exciting things you see on the horizon in the realm of IBD management? 40:26 •    Thank you, Miguel 42:55 •    Thanks for listening 45:11 Miguel Regueiro, MD, is the chief of the Digestive Disease Institute at Cleveland Clinic, and professor in the department of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Regueiro, follow @MRegueiroMD on X. Disclosures: Berry and Chey report no relevant financial disclosures. Regueiro reports being on the advisory boards of and consulting for Abavax, Abbvie, Amgen, Biocon, BMS, Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), Celgene, Celltrion, Gilead, Genentech, Johnson and Johnson, Lilly, Merck, Organon, Pfizer, Prometheus, Roche, Salix, Sanofi, Takeda and UBC.

Về nội dung thì những ai thường sáng suốt trong hành động, nói năng, suy nghĩ gọi là quy y Phật (Tuệ). Thường đủ trầm tĩnh để hành động nói năng suy nghĩ theo sự thật là quy y Pháp (Định). Và thường hiền thiện, chánh trực trong hành động nói năng suy nghĩ là quy y Tăng (Giới). Vậy quy y chính là thân khẩu ý trở về nương tựa nơi 3 đức tính quý báu đó là bản tâm sáng suốt, định tĩnh, trong lành mà Đức Phật gọi là Tâm Chói Sáng (Pabhassara Citta) nơi chính mình chứ không phải nương tựa ai khác. Như Đức Phật dạy trong Kệ Pháp Cú rằng: Tự mình nương tựa mình Không nương tựa ai khác Khi tự mình thuần tịnh Là chỗ nương khó được. Trích trong bài nói chuyện: " Niềm Tin và Niềm Vui Chuyển Hoá" https://open.spotify.com/episode/3XSFlp7dtnzwFak9iLoM1K?si=dd8d58eea4c04ca8#nguyễnduynhiên, #minhtánh, #conđườngchuyểnhoá, #chữalành,

Mitochondria give cells over 90% of their energy. Without proper energy cells cannot carry out their functions. Mitochondrial Dysfunction vs Mitochondrial Disease Mitochondrial dysfunction simply means that the mitochondria are not working correctly. Mitochondrial disease is the term used when the primary cause of mitochondrial dysfunction resides in the mitochondria. Mitochondrial disease is generally genetic. It can be inherited from either or both parents. A special type of mitochondrial disease is caused by mutations on the mitochondrial DNA, and is inherited only from the mother. When the primary cause of mitochondrial dysfunction resides outside the mitochondria, mitochondrial dysfunction is called “secondary” (to something else). Symptoms of Mitochondrial Dysfunction Cellular energy is necessary for the function of all cells, but is particularly critical for nerve and muscle. Both nerve and muscle are important in GI function, thus cyclic vomiting, constipation, diarrhea, poor GI mobility, and other digestive disorders are common. Additional potential complications of mitochondrial dysfunction include chronic fatigue, neuropathic pain, depression, autistic regression, seizures, hypoglycemia, visual and hearing difficulty, depression, anxiety, panic disorder, intellectual disability, and dysautonomia. Mitochondrial Triggers Mitochondrial dysfunction can be genetic, but even then, disease is often triggered by the environment. Viral infections are among the most common triggers of mitochondrial dysfunction. Additional potential triggers are other infections (e.g. lyme bacteria), vaccinations, toxins, anesthesia, and any other significant stressor. In order situations, mitochondrial dysfunction can be acquired. In fact, stroke and heart attack involve mitochondrial dysfunction, whereas cells are receiving insufficient oxygen for required energy metabolism. Many environmental toxins can poison mitochondria as well, including some pesticides... Click Here or Click the link below for more details! https://naturallyrecoveringautism.com/223

Send us a textIn this episode, Alyssa dives deep into the journey of moving beyond food fear to embrace true food freedom while supporting sustainable gut health. This empowering discussion is perfect for anyone who's struggled with restrictive diets, food reactivity, or chronic gut health challenges. With practical advice, actionable strategies, and a wealth of knowledge, this episode offers a roadmap to break free from restrictive eating and reclaim your relationship with food.Resources MentionedFree Gut-Building Veggie Mash Recipe: A simple, low-FODMAP-friendly recipe designed to improve gut diversity without overwhelming sensitive systems.DM “GUT CHECK” on Alyssa's Instagram for a personalized quiz and free meal plans & resources to kickstart your gut healing journey.Check out Alyssa's FREE Masterclass “Why your gut still isn't better - the real reason you feel stuck here. Find Alyssa on: Instagram, LinkedIn, Facebook, Pinterest  -If you're enduring uncomfortable, painful, and embarrassing GI symptoms and feel like you've tried everything, Alyssa uses a specialized approach to help people who've gone from doctor to doctor finally find relief. Book your 15-minute strategy call for FREE here.Tune in and subscribe to "The Gut Health Dialogues" for inspiring client transformation stories and expert insights into gut health. Leave a review—Your support will help Alyssa empower more people with the knowledge and tools to take control of their gut health and reclaim their lives. Looking for a supportive Gut Health community? Alyssa is building a community committed to helping people overcome their digestive symptoms by addressing the root cause using food and nutrition. Join Alyssa's FREE Facebook Community here.

If bladder issues in menopause are keeping you from jumping for bone density or for jumping for joy. Or if laughing and sneezing or a need to consider hydration needs against access to a bathroom are real life and every day concerns you… we've got you today.  Bladder issues in menopause don't need to keep you from activities, and they may come with signs and symptoms that aren't the obvious urgency, burning or leakage. The information here about testing beyond traditional options just might make you want to re-listen and share this one.    My Guest: Dr Kelly McCann is a board certified internist and pediatrician specializing in functional, integrative and environmental medicine. She graduated Brown undergrad, Tulane Med School, fellowship in Integrative Medicine at the University of Arizona. Her medical practice, the Spring Center, is located in Southern California. She hosted virtual summits on MCAS and can be found on many podcasts, summits and @drkellymccann.   Questions We Answer in This Episode: [00:09:09] What is a bacterial biofilm and how does that relate to bladder issues in women? [00:08:21] How do you know if you have a biofilm colonization? [00:13:26] Can you explain the testing technology and how it differs from a urinalysis and urine culture? [00:25:09] Other than UTIs and bladder issues, what might be some other signs that bacterial biofilms might be an issue?  [00:26:55] Are there other things that we should understand about this? (often associated with hypercoagulability which can mean an increased risk for heart disease) [00:30:58] Are there other options before or instead of antibiotics? If you personally got results back suggesting you do have bacteria, would you go the route of herbs or antibiotics?  [00:35:00] Cost of the test? And is it covered?    Bacterial Biofilm as Bladder Issues in Menopause   What is a Bacterial Biofilm? Mucus-like structures where bacteria live, can be found in the mouth, nose, GI tract, vagina, etc. These bacterial “homes” protect microbes from detection in standard lab tests. That means you can have symptoms, but your test results still show “normal.”   What is Next Generation Sequencing? Gives a complete and accurate picture of what's causing  your symptoms, even when your urinalysis and cultures are ‘normal'. Procedure: Scans the DNA of everything present in your sample (e.g. urine). Matches it to a vast DNA library of known organisms. Identifies exactly which microbes are in your bladder, how many, and in what percentages. Recommends treatment options by checking the medical literature for which antibiotics are effective against each bacteria. MicroGenDX does this test.   Signs You Might Have Biofilm Colonization: Chronic bladder symptoms (urgency, frequency, burning) without a confirmed UTI Recurrent UTIs that don't resolve or keep returning “Normal” urine tests but ongoing discomfort Other unexplained inflammation-driven symptoms like fatigue, rashes, headaches, joint pain, and more.   Relation to Heart Disease: Bacteria can travel from brushing your teeth and can end up in your coronary arteries and bladder. Biofilms can trigger clot formation for individuals who are genetically predisposed to forming clots or fibrin mesh. Systemic inflammation risk for individuals with low-level bacterial colonization that their body   Connect with Kelly: Website - Dr. Kelly McCann Website - The Spring Center Facebook - Dr. Kelly McCann Instagram - @drkellymccann    Other Episodes You Might Like: Previous Episode - Solving Sleep Issues with CBD and Other Perimenopause Symptom Solutions Next Episode - What Stem Cell Therapy Taught Me About Recovery, Mindset, and Reinventing Downtime More Like This - True Core Confidence: Revolutionizing Pelvic Floor Fitness After 40   Resources: Short & Easy Exercise videos in this 5 Day Flip Challenge. Don't know where to start? Book your Discovery Call with Debra.  

Dr. Shaalan Beg and Dr. Kristen Ciombor discuss practice-changing studies in GI cancers and other novel treatment approaches that were presented at the 2025 ASCO Annual Meeting. Transcript Dr. Shaalan Beg: Hello, I'm Dr. Shaalan Beg, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas, Texas. There were some remarkable advances in gastrointestinal cancers that were presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Kristen Ciombor to discuss some exciting GI data. Dr. Ciombor is the Ingram Associate Professor of Cancer Research and a co-leader of Translational Research and the Interventional Oncology Research Program at the Vanderbilt Ingram Cancer Center. Our full disclosures are available in the transcript of this episode. Dr. Ciombor, it's great to have you on the podcast today. Dr. Kristen Ciombor: Thanks, Dr Beg. It's great to be here. Dr. Shaalan Beg: Alright, let's kick it off. Big year for GI cancers. We'll start off with LBA1. This was the ATOMIC study sponsored by NCI and the National Clinical Trials Network (NCTN) and the Alliance group. This is a randomized study of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for stage III mismatch repair deficient colorectal cancer. Dr. Kristen Ciombor: I think this study was really definitely practice-changing, as you can tell because it was a Plenary. But I do have some concerns in terms of how we're actually going to implement this and whether this is the final answer in this disease subtype. So, as you said, the patients were enrolled with stage III resected mismatch repair deficient colon cancer, and then they were randomized to either modified FOLFOX6 with or without atezolizumab. And that's where it starts to become interesting because not many of us give FOLFOX for 6 months like was done in this study. Obviously, the study was done over many years, so that was part of that answer, but also the patients received atezolizumab for a total of 12 months. So the question, I think, that comes from this abstract is, is this practical and is this the final answer? I do think that this is practice-changing, and I will be talking to my patients with resected mismatch repair deficient colon cancer about FOLFOX plus atezolizumab. I think the big question is, do these patients need chemotherapy? And can we do a neoadjuvant approach instead? And that's where we don't have all the answers yet. Dr. Shaalan Beg: Yeah, but it has been great to see immunotherapy make its way into the adjuvant space after having made such a big impact in the metastatic space, but still some unanswered questions in terms of the need for chemotherapy and then the duration of therapy, which I guess we'll have to stay tuned in for the next couple of years to to get a lot of those questions answered. Dr. Kristen Ciombor: Yeah, but a big congratulations to the study team, to the NCTN, the NCI. I mean, this is really a great example of federally funded research that needs to continue. So, great job by the study team. The DFS 10% difference is really very large and certainly a practice-changing study. Dr. Shaalan Beg: Yeah, and and sticking with colon cancer, and and this another federally funded study, but this time funded by a Canadian cancer clinical trials group was LBA3510. This is the CHALLENGE study. It's a randomized phase 3 trial of the impact of a structured exercise program on disease-free survival for stage III or high-risk stage II colon cancer. This study got a lot of buzz, a lot of mainstream press coverage, and a lot of discussions on what that means for us for the patients who we're going to be seeing next week in our clinic. What was your takeaway? Dr. Kristen Ciombor: Yeah, this is a really interesting study, and I was so glad to see it presented because this partially answers one of the questions that patients always have for us in clinic, right? You know, once they've completed their standard chemotherapy and surgery, what else can they do to help prevent recurrence? And so we've always known and sort of extrapolated that healthy lifestyle habits are good, but now we have data, particularly in these patients. Most of them were stage III colon cancer patients, those had high-risk stage II cancer. And basically, the goal was to increase their physical activity by at least 10 MET hours per week. So, my big question, of course, as I came into this presentation was, “Okay, what does that mean exactly? How does that translate to real life?” And really what the author presented and explained was that basically most patients could hit their target by adding a 45- to 60-minute brisk walk 3 to 4 times a week. So I think this is very approachable.  Now, in the confines of the study, this was a structured exercise program, so it wasn't just patients doing this on their own. But I do think kind of extrapolating from that, that this is very achievable for most patients. And not only did this prevent recurrence of their prior cancer, but actually the rate of new primary cancer diagnoses, was less, which is really interesting, especially in the breast and prostate cancer. So this was a really interesting, and I think practice-changing study as well, especially given that this is something that most patients can do. Dr. Shaalan Beg: Yeah, and there was a lot of discussion in the hallways after the presentation in terms of how this really changes our existing practice because most folks already recommend exercise as a way for improving outcomes in cancer patients. So we've already been doing that. Now we have some data on how much it can impact the benefit. But there was some discussion about what the actual degree of impact was. There was a drop-off rate in terms of how long folks were able to stick with this exercise regimen. But you've seen this in clinic when someone have their surgery, they have their chemotherapy, they've been so intimately involved with the oncology world, with the oncology practice, and they somehow feel that they're being let loose into this mean, angry world without any guidance and they're looking for something to do. “What more can I do in terms of my lifestyle?” And then here we have very solid data, as solid as can be for an intervention like exercise, showing that there is an impact and you can give a prescription for exercise when someone wraps up their chemotherapy for colon cancer, thanks to the study. Dr. Kristen Ciombor: Yeah. It was a great study. Dr. Shaalan Beg: Moving to gastroesophageal cancer, another late-breaking abstract. This is LBA5. The MATTERHORN trial was a phase 3 trial of durvalumab plus FLOT for resectable GE junction and gastric cancer. And again, another area where immunotherapy has made an impact, and here we're seeing it move closer for earlier-stage disease. What was your take-home for the MATTERHORN trial? Dr. Kristen Ciombor: Yeah, so this study looked at neoadjuvant perioperative durvalumab plus our current standard chemotherapy of FLOT versus placebo plus FLOT. And this was a large study, almost 1,000 patients were randomized. And the primary endpoint was event-free survival, and it was definitely met in favor of the D + FLOT arm, as Dr. Klempner discussed after Dr Janjigian's presentation. I do think there are still some unanswered questions here. Overall survival is not yet mature, so we do have to wait and see how that shakes out. But it's very interesting and kind of is reflective of what, as you said, we're looking at earlier and earlier lines of therapy, particularly with immunotherapy, in these GI cancer spaces. So it makes a lot of sense to test this and and to look at this. So the toxicity was pretty similar to what we would expect. Primary endpoint was met, but again, we'll have to wait and see what the survival data looks like. Dr. Shaalan Beg: Yeah, and in oncology, we know, especially for treatment that does add additional cost, it does add additional potential toxicity that we want to see that overall survival nudged. I did see some polls on social media asking folks whether their practices changed from this, and I think the results were favoring adding durvalumab for this group of patients but understanding that there are caveats to the addition of treatments and the eventual FDA approval in that indication as well. Dr. Kristen Ciombor: Exactly. I completely agree with that. Dr. Shaalan Beg: All right. How about we stick with gastroesophageal cancer? LBA4002 was trastuzumab deruxtecan versus ramucirumab plus paclitaxel for second-line treatment in HER2-positive unresectable or metastatic gastric cancer or GE junction cancer. This was the DESTINY-Gastric04 study. And again, antibody-drug conjugates making a big impact across different diseases. And here we have more data in the HER2-positive gastric cancer space. Your thoughts on this study? Dr. Kristen Ciombor: Yeah, so this is a really important space in gastroesophageal cancer because the HER2 positivity rate is fairly high as compared to some of our other tumor types. So, I do think one of the important things was that patients did have biopsy confirmation of HER2 status, which was very important, and then they were randomized to either T-DXd versus the kind of second-line standard of ramucirumab-paclitaxel. So this was a great practical study and really answers a question that we had for a while in terms of does anti-HER2 therapy in the second-line really impact and improve survival. So we did see a statistically significant improvement favoring T-DXd. I do think it's always important to look at toxicity, though, too. And there was about almost 14% rate of interstitial lung disease, which of course is the most feared toxicity from some of these antibody-drug conjugates, especially T-DXd. So I do think it's important to keep that in mind, but this is definitely a great addition to the armamentarium for these HER2-positive patients. Dr. Shaalan Beg: And pancreas cancer was on the stage after a very long time with a positive clinical trial. This is Abstract 4006. These were preliminary results from a phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone for previously untreated metastatic pancreas cancer. This is a frontline clinical trial of gemcitabine/nab-paclitaxel plus/minus the study drug. There were other cohorts in this study as well, but they reported the results of their part 3B arm. And great to see some activity in the pancreas space. And your thoughts? Dr. Kristen Ciombor: Yeah, we definitely need better treatments in pancreas cancer. This was a very welcome presentation to see. The elraglusib is an inhibitor of GSK-3beta, and it's thought that that mediates drug resistance and EMT. And so this is, I think, a perfect setting to test this drug. So patients basically were randomized. Patients with metastatic pancreas cancer were randomized 2: 1 to gemcitabine/nab-paclitaxel plus or minus this elraglusib. So, what we saw was that overall survival was better with the addition of this new drug. And overall, not only the 1-year overall survival, but also median overall survival.  The thing that was interesting, though, was that we saw that the overall survival rates were 9.3 months with the combination versus 7.2 months with just gemcitabine/nab-paclitaxel. And that's a little bit lower than we've seen in other studies. So, not sure what was going on there. Was it the patients that were a bit sicker? Was it a patient selection, you know, thing? I'm not really sure how to explain that so much. Also, the toxicity profile was much higher in terms of visual impairment, with over 60% of patients being treated with the combination versus 9% with gemcitabine/nab-paclitaxel. So these were mild, grade 1 and 2, but still something to be cautious about. Dr. Shaalan Beg: And especially with this being a phase 2 trial, making sure that in a larger study we're able to better evaluate the toxicity and see if the control arm in the larger confirmatory study performs differently will be really important before this compound makes it to the clinic in our space. But very exciting to see these kinds of results for pancreas adenocarcinoma. Dr. Kristen Ciombor: Yeah. Dr. Shaalan Beg: We've talked, it seems, a couple of times on this podcast about the BREAKWATER clinical trial. We did hear PFS and updated OS data, updated overall survival data on first-line encorafenib plus cetuximab plus modified FOLFOX6 for BRAF-mutated colorectal cancer. This was LBA3500. And eagerly anticipated results – we have all previously heard the progression-free survival results – but here we heard updated overall survival results, and very well-received study it seemed from the audience that time. So what are your takeaways on the updated results for BREAKWATER? Dr. Kristen Ciombor: In my opinion, this was one of the most practice-confirming studies. As you mentioned, we've already seen some of the preliminary data of BREAKWATER at prior meetings. But really what was particularly impactful for me was the median overall survival with the BREAKWATER regimen. So, again, patients received FOLFOX, encorafenib cetuximab in the first line if they had BRAF-mutated V600E-mutated colorectal cancer. And the median PFS was 12.8 months, which was actually really remarkable in this traditionally very aggressive, poor prognosis subtype of tumors. So, by seeing a median overall survival of 30.3 months was just incredible, in my opinion. Just a few years ago, that was considered the median overall survival for all comers for metastatic colorectal cancer. And we know the median overall survival was more in the less than 12 months range for BRAF. So this was incredibly impactful, and I think should be absolutely practice-changing for anyone who is eligible for this regimen.  I think again, where the practice meets the study is what's kind of important to think about too, how long did patients get FOLFOX, and certainly it adds toxicity to add a BRAF-targeted regimen on top of FOLFOX already. So, one of the other interesting things about the study, though, was that even though it didn't complete treatment, they actually did look at encorafenib/cetuximab alone and in the first line without chemotherapy. And those preliminary results actually looked okay, especially for patients who might not be able to tolerate chemotherapy, which we certainly see in practice. So, overall, definitely more data. And I agree that it's certainly practice-changing. Dr. Shaalan Beg: And it completely, as you mentioned, changes the outlook for a person who's diagnosed with BRAF-mutated metastatic colon cancer today versus even 7 or 8 years ago. Dr. Kristen Ciombor: And we're seeing this over and over in other subtypes too, but how you choose to treat the patient up front really matters. So really giving the right regimen up front is the key here. Dr. Shaalan Beg: And along the same lines, Abstract 3501 wanted to answer the question on whether people with MSI-high metastatic colorectal cancer need double checkpoint inhibitor therapy or is single therapy enough. So this [CheckMate-8HW] study compared nivo plus ipi with nivo alone, nivo monotherapy for MSI-high metastatic colorectal cancer. And we've known that both of these are fairly active regimens, but we also know the chance of immune-related adverse events is significantly higher with combination therapy. So this was a much-needed study for this group of patients. And what were your takeaways here? Dr. Kristen Ciombor: This, of course, has been really nivo-ipi in the first-line MSI-high metastatic colorectal cancer is now a standard of care. And not everybody is eligible for it, and there could be reasons, toxicity reasons, and other things too. But as we've been seeing for the last couple of years, immunotherapy clearly beats chemo in this space. And now looking at doublet versus single immunotherapy treatment in the first line, I think really nivo-ipi does beat out monotherapy. I will say, however, there is a caveat in that we still haven't seen the nivo-ipi versus nivo in the first line. So what has been presented thus far has been across all lines of therapy, and that does muddy the waters a little bit. So definitely looking forward and and we've asked this many times and based on the statistical plan and and what not, you know, we just haven't seen that data yet. But I do think it's becoming increasingly important to consider doublet immunotherapy for these patients as long as there are no contraindications. With the again, with the caveat that we have to have these toxicity discussions in the clinic with patients because many patients can tolerate it, you know, this regimen fairly well, but there can be very severe toxicities. So, I think an informed discussion should really be had with each patient before moving forward. Dr. Shaalan Beg: Yeah, informed decision, making them aware of the potential of real significant toxicities, immune-related toxicities with double therapy. But I am curious in your practice, how often do you see people choosing doublet therapy as frontline? Dr. Kristen Ciombor: So patients are really savvy, and a lot of times they've heard this data before or have come across it in patient advocacy groups and other things, and it's really nice to be able to have that conversation of the risk versus benefit. So I will say not all of my patients choose doublet, and many of them are still cured with immunotherapy monotherapy. So the big question there is, will we ever understand who actually needs the doublet versus who can still be cured or have very good long-term outcomes with just the single agent? And that has not been answered yet. Dr. Shaalan Beg: What a great point. So the last abstract I was hoping we could talk about is POD1UM-303 or the INTERAACT2 subgroup analysis and impact of delayed retifanlimab treatment for patients with squamous cell carcinoma of the anal canal. What were your thoughts here? Dr. Kristen Ciombor: This was a study, actually we saw at ESMO, we saw the primary data at ESMO last year, and this was an update with some exploratory analyses. But this was really an important study because once again, we're looking at immunotherapy in later lines of therapy. That's how we started looking at and investigating immunotherapy, and now we're moving it up and up in the treatment course. So this was a study of carboplatin/paclitaxel plus or minus retifanlimab. Actually it was retifanlimab versus placebo. And it was a positive study, as we heard last year. This actually led to FDA approval of this regimen last month, just before ASCO, and it has now been incorporated in the NCCN guidelines as the preferred first-line option.  So what I thought was important from the additional data presented at ASCO was looking at the different subgroups, it did not appear that patients with liver mets or not had different outcomes. So that was really good to see because sometimes in colon cancer we see that immunotherapy doesn't work as well when patients have liver mets. And interestingly, because we use immunotherapy in anal cancer without any biomarkers, unlike with colon cancer or some of the other tumor types, also the authors looked at PD-L1 status, and it did look like maybe patients did a little bit better if they had higher PD-L1 expression, but patients still could benefit even if they were PD-L1 negative. So that was important, I think, and we will continue to see further data come out from this study. I want to mention also that EA2176 just completed accrual, so that was carbo-taxol plus or minus nivolumab. And so we should be seeing that data sometime soon, which will hopefully also confirm the ongoing role for immunotherapy in the first-line setting for anal cancer. Dr. Shaalan Beg: That was a fantastic review. Thank you, Dr Ciombor. Thanks for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Kristen Ciombor: Thanks for having me here. Dr. Shaalan Beg: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Shaalan Beg  @ShaalanBeg  Dr. Kristen Ciombor @KristenCiombor Follow ASCO on social media:    @ASCO on Twitter   @ASCO on BlueSky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Shaalan Beg:   Consulting or Advisory Role: Ipsen, Cancer Commons, Foundation Medicine, Science37, Nant Health, Lindus Health Speakers' Bureau: Sirtex Research Funding (Inst.): Delfi Diagnostics, Universal Diagnostics, Freenome Dr. Kristen Ciombor: Consulting or Advisory Role: Pfizer, Incyte, Exelixis, Bayer, ALX Oncology, Tempus, Agenus, Taiho Oncology, Merck, BeiGene Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calthera, Genentech, Seagen, Syndax Travel, Accommodations, Expenses: Incyte, Tempus

Loài thú có túi Leadbeater nhỏ đến mức có thể nằm gọn trong lòng bàn tay, và từng hai lần bị cho là đã tuyệt chủng. Giờ đây, một quần thể mới vừa được phát hiện tại tiểu bang New South Wales, và cuộc chạy đua bảo tồn chúng đang bắt đầu.

#Bàigiảng của Lm #GiuseĐặngChíLĩnh trong thánh lễ mừng Sinh nhật thánh Gioan Tẩy Giả, cử hành lúc 17:30 ngày 24-6-2025 tại Nhà nguyện Trung tâm Mục vụ #TGPSG

Not all sports dietitians are created equal—especially when it comes to working with young, developing gymnasts. In this episode, I'm breaking down why your gymnast needs a pediatric/adolescent sports dietitian, not just any sports RD who's used to fueling adult athletes. The nutritional needs of gymnasts are not the same as grown adults like college or professional athletes. Your gymnast is still growing, developing, and navigating puberty—all while training like an elite athlete. That's a unique combination that deserves a specialized approach.As a parent, you want to work with someone who not only understands fueling for performance, but also knows how to support long-term health, hormonal development, injury prevention, and medical nuances like growth delays, allergies, or GI issues—all of which are way more common in this sport than most people realize. That's what sets a pediatric/adolescent sports dietitian apart.We're doing all the sports nutrition things—helping with fueling before, during, and after practice and maximizing recovery. But there's so much more to layer onto that. We're also doing what's called medical nutrition therapy, making sure these gymnasts are growing and developing on time. In this episode you'll learn about: Why young gymnasts aren't just “small adults” and can't be treated as such nutritionally even if they're athletesThe difference between a general sports dietitian and a pediatric/adolescent sports dietitian and all the training requiredWhy nutrition for gymnasts must be individualized and age-appropriate and can't be generalized  Links & Resources    The Balanced Gymnast® Program for level 5-10 female gymnasts Episode 129: Why gymnast growth charts are so important to success in the sportEpisode 112: Is your “tiny gymnast” actually underfueled, or growing normally for them?Connect with Christina on Instagram @the.gymnast.nutritionist or christinaandersonrdn.com

In this episode of the Full of Beans Podcast, Han is joined by Sarah Elder, a registered eating disorder dietitian and advanced clinical practitioner, to explore the real role of dietitians in eating disorder recovery.Together, we unpack what it means to offer trauma-informed, compassionate, and culturally appropriate nutritional care, far beyond simply providing meal plans. Sarah also shares her mission to make ED nutrition education more accessible and effective for all professionals working in the field.Key Takeaways:Why eating disorder dietitians do so much more than write meal plansThe difference between nutrition education and psychoeducationWhat trauma-informed nutritional care looks like in practiceThe impact of GI issues in recovery and how dietitians can helpWhy collaborative, values-based support is essential for long-term healingThe importance of cultural and personal context in meal planningWhy Sarah believes “real food” must reflect real people's livesTimestamps:04:30 – Why trauma-informed, accessible ED nutrition training matters 08:00 – Psychoeducation vs. nutrition education in recovery 13:00 – GI issues during recovery & how to approach them 16:45 – What trauma-informed care means in practice 23:40 – Challenges of restrictive diets & misunderstood advice 27:00 – Collaborating with therapy & OT teams in care 29:00 – Dismantling the fear of seeing a dietitian 32:10 – Standard meal plans vs. individualised support 36:30 – Cultural food practices and integration in recovery Trigger warning: This episode discusses eating disorders and gastrointestinal distress.Connect with Us:Subscribe to the Full of Beans Podcast hereFollow Full of Beans on Instagram hereConnect with Sarah:Sarah's Website Sarah's Instagram (@saraheldernutrition)Read our latest blog hereFurther Resources: First Steps EDThank you for listening and being part of this important conversation!If you loved this episode, don't forget to subscribe, leave a review, and share it with someone who might benefit!Sending positive beans your way, Han

When in one's neuroendocrine cancer journey might a clinical trial be considered? What factors influence treatment decisions, including whether to pursue a clinical trial? Dr. Alexandria Phan, medical oncologist at the Medical College of Wisconsin, offers thoughtful guidance on when and how clinical trials fit into the neuroendocrine cancer journey. This episode helps demystify the clinical trial process and empowers patients to engage in meaningful, proactive conversations with their care teams.MEET DR. ALEXANDRIA PHANDr. Alexandria Phan is a hematologist and medical oncologist at the Froedtert & Medical College of Wisconsin. Clinical practice, clinical research and education are three pillars important to Dr. Phan's approach to cancer care. Her areas of focus for clinical research and patient care are neuroendocrine tumors and malignancies of the gastrointestinal system. She has held several leadership positions, including cancer center director, founding program director for Hematology-Oncology fellowship, medical director of clinical research, and national director for GI cancer program.For more information, visit NCF.net.

What are the Brazilian Jiu-Jitsu traditions and etiquette you need to know?If you love the Podcast, share it with a friend! You can also leave us a 5 5-star rating in Spotify or Apple Podcasts. https://open.spotify.com/show/3IHT3BNicukNtCVa3AAwBI https://podcasts.apple.com/us/podcast/beauty-and-the-gi/id1458389465?mt=2 Learn More about Roll Model Grappling Camp https://rollmodelswanted.com/ New to the Podcast? Start with these episodes https://open.spotify.com/playlist/19P8KcTyNTIA0hZPQYAbuN?si=f841456b4906439f https://beautyandthegi.libsyn.com/category/Start+Here Subscribe to Beauty and the Gi on YouTube or in your Favorite Podcasting App https://episodes.fm/1458389465 YouTube https://www.youtube.com/channel/UC7EBCzi7znNuvxKlpLvue-w Apple Podcasts https://podcasts.apple.com/us/podcast/beauty-and-the-gi/id1458389465?mt=2 Spotify https://open.spotify.com/show/3IHT3BNicukNtCVa3AAwBI Beauty and the Gi on Audible https://www.audible.com/pd/Beauty-and-the-Gi-Podcast/B08JJMFS1D? Connect with Jen and AJ Beauty and the Gi Podcast on Instagram @beautyandthegipodcast Jen on Instagram @brassybroadjen Jen on TikTok @brassybroadjen AJ on Instagram @ajclingerman AJ on TikTok @roll_model Roll Model Grappling on Instagram @rollmodelgrappling Connect with Megan Timler and Kindra Barrett on InstagramMegan Timler - @nuttmeg012Kindra Barrett - @kindra_barrettTheme Music by Jen at The Brassy Broadcasting Company Disclaimer: The Beauty and the Gi podcast and content posted by Beauty and the Gi is presented solely for general informational, educational, and entertainment purposes. It is not intended as a substitute for the advice of a physician, professional coach, psychotherapist, or other qualified professional, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical or mental health condition they may have and should seek the assistance of their healthcare professionals for any such conditions.